Cargando…
PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open
In the last three months, the whole scientific community has shifted its focus to the fight against the COVI-2 infection (COVID-19) trying to use different medications to save the patients' life. In some studies, the results were completely inconclusive, as in the case of chloroquine. However,...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367667/ https://www.ncbi.nlm.nih.gov/pubmed/32688139 http://dx.doi.org/10.1016/j.biopha.2020.110536 |